Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Non-Current Deffered Revenue (2020 - 2022)

Historic Non-Current Deffered Revenue for Therapeutics (RAPT) over the last 3 years, with Q1 2022 value amounting to $241000.0.

  • Therapeutics' Non-Current Deffered Revenue fell 8882.71% to $241000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $241000.0, marking a year-over-year decrease of 8882.71%. This contributed to the annual value of $2.2 million for FY2021, which is 160.18% down from last year.
  • As of Q1 2022, Therapeutics' Non-Current Deffered Revenue stood at $241000.0, which was down 8882.71% from $2.2 million recorded in Q4 2021.
  • In the past 5 years, Therapeutics' Non-Current Deffered Revenue registered a high of $3.3 million during Q1 2020, and its lowest value of $241000.0 during Q1 2022.
  • Its 3-year average for Non-Current Deffered Revenue is $2.1 million, with a median of $2.2 million in 2021.
  • Per our database at Business Quant, Therapeutics' Non-Current Deffered Revenue crashed by 160.18% in 2021 and then plummeted by 8882.71% in 2022.
  • Quarter analysis of 3 years shows Therapeutics' Non-Current Deffered Revenue stood at $2.2 million in 2020, then dropped by 1.6% to $2.2 million in 2021, then tumbled by 88.79% to $241000.0 in 2022.
  • Its Non-Current Deffered Revenue was $241000.0 in Q1 2022, compared to $2.2 million in Q4 2021 and $2.1 million in Q3 2021.